Haematology patients infected with SARS-CoV-2, pretreated with eculizumab or siltuximab, develop oligosymptomatic disease
| Autor: | Sergiu P. Paşca, Adrian P. Trifa, Laura Urian, Ciprian Tomuleasa, Delia Dima, Anca Bojan, Ovidiu Balacescu, Gabriela Mester, Mihnea Zdrenghea, Sabina Iluta |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
viruses Hepatitis C virus Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Disease medicine.disease_cause 030226 pharmacology & pharmacy Siltuximab 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine medicine Humans 030212 general & internal medicine General Pharmacology Toxicology and Pharmaceutics Abdominal obesity Hepatitis B virus Hematology SARS-CoV-2 COVID-19 Eculizumab chemistry medicine.symptom medicine.drug |
| Zdroj: | European Journal of Hospital Pharmacy |
| ISSN: | 2047-9956 |
| Popis: | We have read with great interest the publication from Palanques-Pastor and colleagues,1 and due to the interest in this subject we would like to mention that we also observed no SARS-CoV-2 symptoms in a patient with multicentric Castleman’s disease. The patient was a woman diagnosed in her 20s, who initially presented with sweating, fatigue, dyspnoea at medium effort and weight gain. At the clinical exam, the only concerning observation was that the patient presented with abdominal obesity. Aside from this, the patient had normal respiratory, cardiac and digestive examinations. She was negative for the following viruses: HIV, human herpesvirus 8, hepatitis B virus and hepatitis C virus, and received four cycles of anti-interleukin-6 (IL-6) therapy with siltuximab. She later tested positive for SARS-CoV-2 … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|